Medicine & Health

Ganesh Chand, an assistant professor at WashU Medicine Mallinckrodt Institute of Radiology, will study why some Alzheimer’s patients experience neuropsychiatric symptoms such as apathy and depression.

In a study published in Nature Neuroscience, researchers at WashU Medicine showed in mice that Alzheimer’s disease upended the daily activity patterns of hundreds of genes in cells that regulate key functions in the brain.

Eva Klinman, MD, PhD, an instructor in the Department of Neurology at WashU Medicine, has been named a 2025 STAT Wunderkind by STAT News for her exceptional contributions to understanding the mechanisms of brain aging and neurodegeneration.

WashU Medicine researchers led by Erik Musiek, MD, PhD, discovered in mice that inhibition of a protein that controls the daily cycling of metabolism and inflammation decreases neurodegeneration in Alzheimer’s disease.

A scientist at Washington University in St. Louis has received a grant from the Alzheimer’s Association to support his research investigating the electrochemistry of neurotoxic protein assemblies.

Andrew S. Yoo, the Phil and Sima Needleman Distinguished Professor of Developmental Biology at WashU Medicine, and Zhao Sun, a staff scientist in Yoo’s laboratory, have received the Morby Prize from the Cure Alzheimer’s Fund in recognition of their groundbreaking paper that describes a novel method to study aged neurons.

WashU Medicine researchers have identified biomarkers of Alzheimer’s, Parkinson’s and frontotemporal dementia from blood plasma, suggesting new therapeutic avenues.

WashU Medicine researcher Benjamin Garcia will receive $18.5 million from the National Institutes of Health (NIH) to study how long-lived mammals stay healthy into old age.

A new study by WashU Medicine researchers suggests that lemborexant and sleep aids that work the same way could help treat or prevent damage caused by harmful buildup of the protein tau in multiple neurodegenerative diseases, including Alzheimer’s.

In a recent study, WashU Medicine researchers found adverse events were rare and manageable among patients with very mild or mild Alzheimer’s disease who received infusions of a next-generation Alzheimer’s medication.